
Claims

1. A compound of Formula **(I)**:



(I)

or a pharmaceutically acceptable salt thereof, where:

$\mathbf{R^1}$ is a cyclohexyl, tetrahydrofuranyl or oxanyl ring, each of which is optionally substituted by one or more groups selected from hydroxyl, methoxy and methyl; and

$\mathbf{R^2}$ is hydrogen or methyl.

2. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein $\mathbf{R^1}$ is oxanyl.

3. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 2, wherein $\mathbf{R^1}$ is oxan-4-yl.

4. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein $\mathbf{R^1}$ is cyclohexyl.

5. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 4, wherein $\mathbf{R^1}$ is 1-hydroxy-1-methyl-cyclohex-4-yl.

6. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein $\mathbf{R^2}$ is hydrogen.

7. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:
9-((1r,4r)-4-hydroxycyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
9-((1s,4s)-4-hydroxycyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one;
2-((2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7-methyl-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one;
9-((1s,4s)-4-methoxycyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
9-((1r,4r)-4-methoxycyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
(S)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-3-yl)-7,9-dihydro-8H-purin-8-one;
(R)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-3-yl)-7,9-dihydro-8H-purin-8-one;
9-((1r,4r)-4-hydroxy-4-methylcyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
9-((1s,4s)-4-hydroxy-4-methylcyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one;
(S)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydrofuran-3-yl)-7,9-dihydro-8H-purin-8-one;
9-((1s,4s)-4-hydroxy-1-methylcyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one; and
9-cyclohexyl-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one.

8. 7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one or a pharmaceutically acceptable salt thereof.

9. 7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one.

10. A crystalline form of 7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one.

11. The crystalline form, as claimed in claim 10, wherein the crystalline form has an XRPD pattern substantially as shown in Figure 1 as measured using CuKα radiation.

12. A crystalline form of 9-((1s,4s)-4-hydroxy-4-methylcyclohexyl)-7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-7,9-dihydro-8H-purin-8-one.

13. The crystalline form, as claimed in claim 12, wherein the crystalline form has an XRPD pattern substantially as shown in Figure 3 as measured using CuKα radiation.

14. A pharmaceutical composition which comprises a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, and at least one pharmaceutically acceptable diluent or carrier.

15. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, for use in therapy.

16. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, for use in the treatment of cancer.

17. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, for use in the treatment of cancer as claimed in claim 16, where the compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof is administered in combination with radiotherapy.

18. A compound of Formula **(I)** or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, for use in the treatment of cancer as claimed in claim 16, where the compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin,

idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736 (durvalumab), AZD1775 AZD6738, AZD1390 and AZD0156.

19. Use of a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, for the manufacture of a medicament for the treatment of cancer.